Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials)

By sjmartinez • June 27, 2023

Anzueto A, Barjaktarevic IZ, Siler TM, Rheault T, Bengtsson T, Rickard K, Sciurba F; ENHANCE investigators. Ensifentrine, a Novel PDE3 and PDE4 Inhibitor for the Treatment of COPD: Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Trials (The ENHANCE Trials). Am J Respir Crit Care Med. 2023 Jun 26. doi: 10.1164/rccm.202306-0944OC. Epub ahead of print. PMID: 37364283.

Tags: COPD, ensifentrine, nebulized, PDE3 and PDE4 inhibitor, Publications, Pulmonary, Critical Care & Sleep Medicine

Hand Swelling and Other Non-Raynaud Phenomenon Symptoms as the Initial Presentation of Systemic Sclerosis: Prevalence and Clinical Associations in Two US Cohorts

Hanif I, Assassi S, Mayes MD, McMahan ZH, Zhang M, Charles J, VanBuren JM, Alvey JS, Ghaffari K, Bernstein EJ, Castelino FV, Chung L, Evnin[...]

Augmenting management of obstructive sleep apnea with consumer wearable devices to increase use of positive airway pressure therapy: a pilot randomized trial

Fung CH, Mak S, Ash G, Der-McLeod E, Ereso J, Naeem S, Liu J, Ghadimi S, Te TT, Chan V, Hurtado J, Wong S, Zeidler[...]

Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis

Kawai K, Muhere CF, Lemos EV, Francis JM. Viral Infections and Risk of Cardiovascular Disease: Systematic Review and Meta-Analysis. J Am Heart Assoc. 2025 Oct[...]